Comparison of Biopsy Results and Surgical Outcomes of Magnetic Resonance Imaging-Guided and Transrectal Ultrasonography-Guided Repeat Biopsy.
10.22465/kjuo.2017.15.2.72
- Author:
Hyunwoo CHUNG
1
;
Wan SONG
;
Jae Ho YOO
;
Min Yong KANG
;
Hwang Gyun JEON
;
Byong Chang JEONG
;
Seong Il SEO
;
Seong Soo JEON
;
Han Yong CHOI
;
Chan Kyo KIM
;
Byung Kwan PARK
;
Hyun Moo LEE
Author Information
1. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. hyunmoo.lee@samsung.com
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Prostatic neoplasms;
Repeat biopsy;
Magnetic resonance imaging;
Transrectal ultrasonography;
Outcomes
- MeSH:
Biopsy*;
Humans;
Magnetic Resonance Imaging;
Neoplasm Grading;
Passive Cutaneous Anaphylaxis;
Prospective Studies;
Prostate;
Prostate-Specific Antigen;
Prostatectomy;
Prostatic Neoplasms;
Retrospective Studies;
Ultrasonography
- From:Korean Journal of Urological Oncology
2017;15(2):72-78
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We compared biopsy results and surgical outcomes of magnetic resonance imaging (MRI)-guided biopsy with transrectal ultrasonography (TRUS)-guided biopsy to demonstrate efficacy of MRI-guided biopsy on previous biopsy negative patients. MATERIALS AND METHODS: We retrospectively reviewed data of 120 patients who were categorized into MRI-guided biopsy groups (n=20) and TRUS-guided biopsy groups (n=100). All patients were diagnosed with prostate cancer (PCa) and had undergone radical prostatectomy (RP) after MRI-guided or TRUS-guided repeat biopsy between January 2010 and March 2016. Detection rate of significant cancer and Gleason score upgrading and downgrading were examined, in addition to biopsy results and subsequent RP outcomes. RESULTS: Median values for prostate-specific antigen level of the TRUS-guided biopsy group and the MRI-guided biopsy group were 6.67 and 5.86 ng/mL (p=0.303), respectively. Median prostate volume of each group (34.1 mL vs. 23.5 mL, p=0.007), number of positive cores (2.0 vs. 3.0, p=0.001) and maximum cancer/core rate (30.0% vs. 60.0%, p<0.001) were statistically different. Positive core rates of each group were 21.9% and 87.1%, respectively. Pathologic T stage was the only variable that showed difference in surgical outcomes (p=0.002). Most of PCa was confirmed as clinically significant PCa after RP in MRI-guided biopsy group (95%). CONCLUSIONS: MRI-guided biopsy showed higher positive core rate and detection rate of clinically significant PCa than TRUS-guided biopsy in repeat biopsy setting. Prospective multicenter large-scale study and accumulation of data is expected to further define superiority of the MRI-guided biopsy.
